Delpharm
Delpharm operates 10 manufacturing plants in France (group total: 17 plants), providing most of the dosage forms available on the market.
With a workforce of 3,700 employees, these industrial sites generate an annual turnover of €545 million (group total: €800 million).
Delriv Port de Boulogne-Billancourt
Face au 9 quai du 4 Septembre
92100 Boulogne-Billancourt
Phone: +33 (0)1 41 09 19 70
Chief Sales Officer
Stéphane Lepeu
Production
- Solids
- Core tablets
- Sugar-coated tablets
- Film-coated tablets
- Effervescent tablets
- Capsules
- High potent tablets
- Hormonal products
- Oncological products
- Granules/Powders
- Sachets
- Compacting
- Granules/Powders
- Sterile Powders
- Liquids
- Solutions, Syrups
- Oral suspensions
- Topical and nasal sprays
- High potent liquids
- Semi solids
- Gels, creams in tubes
- Gels, creams in sticks
- Gels, creams in bottles
- Suppositories/ovules
- Soft gel capsules
- High potent products
- Sterile liquids
- Injectable ampoules final sterilization
- Injectable ampoules aseptic filling
- Injectable vials final sterilization
- Sterile filling vials
- Freeze-drying
- Aseptic eye drops
- Others
- Cell cultures
- Diagnostics
- Impregnated dressings
Development
- Regulatory affairs
- Formulation
- Analytical development
- Process development
- Clinical lots
- Solid pilot
- Liquid pilot
- Semi solid pilot
- Drafting of the AMM dossier
- Validation of analytical methods
- Storage
- Stability study
- Product transfert
- Physico-chemical controls
- Microbiological controls
- Quality controls
- Freeze-drying cycles
- Clinical batch control
- Product Lifecycle Management
Regulatories
- EMA
- ANVISA (Brazil)
- FDA
- PMDA (Japan)
- ANSES-ANMV
- MIT (Russia)
- ISO 13485
- ISO 14001